Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3

Translational and Clinical Outcomes

1st Edition - April 15, 2022

Write a review

  • Editors: Ganji Nagaraju, Sarfraz Ahmad
  • Hardcover ISBN: 9780323992831
  • eBook ISBN: 9780323992848

Purchase options

Purchase options
Available
DRM-free (PDF, EPub)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma: Translational and Clinical Outcomes, Volume Three provides comprehensive information about ongoing research and clinical data on liver cancer. The book presents detailed descriptions about diagnostics and therapeutic options for easy understanding, with a focus on precision medicine approaches to improve treatment outcomes. This updated volume discusses topics such as clinical and safety assessment of HCC patients, liver transplantation as a therapeutic option, immunotherapy interventions, and image-based surveillance. In addition, it discusses immunohistology of HCC-enabled precision medicine and artificial intelligence for hepatocellular carcinomas. This is a valuable resource for cancer researchers, oncologists, graduate students, hepathologists and members of biomedical research who need to understand more about liver cancer to apply in their research work or clinical setting.

Key Features

  • Provides best practices for the management of hepatocellular carcinoma in the clinical setting
  • Discusses emerging treatment approaches based on artificial intelligence and precision medicine tools and techniques
  • Brings updated information on international clinical trials for the treatment of HCC

Readership

Cancer researchers, oncologists. Medical doctors, hepathologists, graduate students

Table of Contents

  • Cover image
  • Title page
  • Table of Contents
  • Copyright
  • Dedication
  • List of contributors
  • About the editors
  • Preface
  • Chapter 1. Nanoparticles for diagnosis and treatment of hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • Chitosan nanoparticles
  • Mesoporous silica nanoparticles
  • Iron oxide nanoparticles
  • Liposomal nanoparticles
  • Solid lipid nanoparticles
  • Gold nanoparticles
  • Titanium oxide nanoparticles
  • Pectin-based nanoparticles
  • mPEG-PLGA-PLL copolymer-based nanoparticles
  • Nanoparticles in clinical trials to treat hepatocellular carcinoma
  • Toxicity
  • Conclusion
  • References
  • Chapter 2. Theranostics application of nanocarriers in hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • Conclusion
  • Acknowledgment
  • Conflict of interest
  • References
  • Chapter 3. Nanoparticle-based theranostics and their role in hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • Pathogenesis
  • Nanotheranostics in hepatocellular carcinoma
  • Conclusions and future perspectives
  • Conflicts of interest
  • References
  • Chapter 4. Therapeutic options for the management of hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • Chemotherapeutic drugs
  • Immunotherapy
  • Phytochemicals
  • Nanomedicines
  • Conclusion
  • References
  • Chapter 5. Targeting hepatocellular carcinoma by small-molecule inhibitors
  • Abstract
  • Abbreviations
  • Introduction
  • Small-molecule inhibitors and their relevance in cancer
  • Conclusion
  • Acknowledgment
  • Conflict of interest
  • Funding
  • References
  • Chapter 6. Curing of liver cancer: an update on the efficacy of bioactive compounds
  • Abstract
  • Abbreviations
  • Background study of liver cancer
  • Introduction
  • Conclusion and future perspectives
  • Conflict of interest
  • References
  • Chapter 7. Plant therapeutics for hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • Biology of liver
  • Histopathology of liver
  • Liver cancer risk factors and diagnosis
  • Natural compounds on liver cancer
  • Conclusion and future outlook
  • Acknowledgments
  • Conflict of interest
  • References
  • Chapter 8. Phytochemicals for hepatocellular carcinoma therapy: from in vitro to clinic
  • Abstract
  • Abbreviations
  • Introduction
  • Genes associated with hepatocellular carcinoma
  • Genes involved in WNT- and TGF-β-signaling cascade
  • Herbs and their secondary metabolites
  • Conclusion
  • Conflict of interest
  • References
  • Chapter 9. Resveratrol for hepatocellular carcinoma therapy
  • Abstract
  • Abbreviations
  • Introduction
  • Structure
  • Source
  • Chemical synthesis
  • Functions of resveratrol
  • Resveratrol as a phytoalexin
  • Resveratrol as a natural phenol
  • Resveratrol as a natural antioxidant
  • Resveratrol as anticarcinogenic agent
  • Reactive oxygen species
  • Role of resveratrol on hepatocellular carcinoma (liver cancer)
  • Conclusions and future perspectives
  • Conflict of interest
  • References
  • Chapter 10. Curcumin: a spice pigment against hepatic cancer
  • Abstract
  • Abbreviations
  • Introduction
  • Curcumin: the golden spice component
  • Biological activity of curcumin
  • Curcumin and liver cancer
  • Limitations and prospects
  • Conclusion
  • Acknowledgments
  • Declarations of interest
  • Funding
  • References
  • Chapter 11. Curcumin formulated nanoparticles for hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • Chemicals involved in hepatocellular carcinoma
  • Curcumin nanoformulations in hepatocellular carcinoma
  • Synthesis of nanoformulations
  • Anticancer properties of curcumin facilitated nanoformulations
  • Conclusion
  • Funding
  • Conflict of interest
  • References
  • Chapter 12. Role of phytoconstituents in the hepatocellular carcinoma management: current perspective, challenges, and future perspectives
  • Abstract
  • Abbreviations
  • Introduction
  • References
  • Chapter 13. Phytonanoformulations for hepatocellular carcinoma therapy
  • Abstract
  • Abbreviations
  • Introduction
  • Nanomedicine
  • Properties of nanoparticles
  • Nanophytochemicals used in cancer treatment
  • Phytochemicals used in the treatment of hepatocellular carcinoma
  • Conclusion
  • References
  • Chapter 14. Immune checkpoint inhibitors for hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • The immunology of hepatocellular carcinoma
  • Immune responses of the liver that promotes tumor cell proliferation
  • Immune checkpoint inhibitors and hepatocellular carcinoma
  • Combination immunotherapy: potential treatment of the future?
  • Conclusion and future perspective
  • Acknowledgments
  • References
  • Chapter 15. Recent advancements in immunotherapy interventions for the management of liver cancer
  • Abstract
  • Abbreviations
  • Introduction
  • Types of immunotherapy
  • Advantages and disadvantages
  • Future direction and conclusion
  • References
  • Chapter 16. Immunotherapy for hepatocellular cancer: a review of current status
  • Abstract
  • Abbreviations
  • Introduction
  • Hepatocellular carcinoma immunology
  • Immune checkpoint inhibitors
  • Checkpoint inhibitors for hepatocellular carcinoma monotherapy
  • Combination treatment
  • Conclusions and future perspective
  • References
  • Chapter 17. Updates on clinical trials for the management of hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • Staging and prognosis in hepatocellular carcinoma
  • Management of hepatocellular carcinoma
  • Second-line systemic therapies
  • Conclusions and future perspectives
  • References
  • Chapter 18. Theranostic and precision medicine for the diagnosis of hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Epidemiology
  • Ultrasound
  • Computed tomography
  • Magnetic resonance imaging
  • Tumor markers
  • Guidelines for hepatocellular carcinoma surveillance
  • Cost-effectiveness of hepatocellular carcinoma diagnostic modalities
  • Conflict of interest
  • References
  • Chapter 19. Precision medicine approaches for treating hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • General information on hepatocellular carcinoma
  • Ablation
  • Embolization
  • Precision medicine definition and use in cancers in general
  • Significance for using precision medicine approaches for treating hepatocellular carcinoma
  • Chemo-resistive mechanisms in hepatocellular carcinoma
  • Liquid biopsy
  • Summary and conclusions
  • Future directions
  • Acknowledgments
  • References
  • Chapter 20. Decoding the functional role of extracellular vesicles in hepatocellular carcinoma: implications in clinical theranostics
  • Abstract
  • Abbreviations
  • Functional role of EVs in hepatocellular carcinoma: from angiogenesis to metastatic organotropism
  • EVs in targeted therapeutic interventions in HCC
  • Conclusion and future prospects
  • Conflict of interest
  • Funding
  • References
  • Chapter 21. Cathepsin B: structure, function, tumorigenesis, and prognostic value in hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • Structure-function properties of cathepsin B
  • Tumorigenesis and metastatic role of cathepsin B in cancers with emphasis on hepatocellular carcinoma
  • Prognostic values of cathepsin B in hepatocellular carcinoma
  • Conclusions and future perspective
  • Conflict of interest
  • References
  • Chapter 22. Chemotherapy for hepatocellular carcinoma—an updated review
  • Abstract
  • Abbreviations
  • Introduction
  • Risk factors and pathogenesis of hepatocellular carcinoma
  • Chemotherapy for hepatocellular carcinoma
  • Sorafenib–a first-line chemotherapeutic agent
  • Immunotherapeutic agents
  • Conclusion
  • Conflict of interest
  • References
  • Chapter 23. Recent advances in medical treatment of hepatocellular cancer
  • Abstract
  • Abbreviations
  • Introduction
  • Lenvatinib
  • Regorafenib
  • Cabozantinib
  • Ramucirumab
  • Bevacizumab plus atezolizumab
  • Nivolumab and nivolumab plus ipilimumab
  • Nivolumab plus ipilimumab
  • Pembrolizumab
  • Sequencing systemic in advanced hepatocellular carcinoma
  • Conclusions and future perspectives
  • References
  • Chapter 24. Recent perspectives on therapeutic significance of microRNAs in hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • Conclusions
  • Acknowledgment
  • References
  • Chapter 25. Pharmacogenomics and outcomes for hepatocellular cancer treatment
  • Abstract
  • Abbreviations
  • Introduction
  • Pathophysiological aspects
  • Guidelines for treatment of hepatocellular carcinoma
  • Challenges in treatment of hepatocellular carcinoma
  • Pharmacogenomic considerations for hepatocellular carcinoma treatments
  • References
  • Chapter 26. Epigenetic biomarkers in diagnosis, prognosis, and treatment of hepatocellular carcinoma
  • Abstract
  • Abbreviations
  • Introduction
  • DNA methylation in hepatocellular carcinoma
  • Histone modifications in hepatocellular carcinoma
  • Conclusion
  • Conflict of interest
  • References
  • Index

Product details

  • No. of pages: 468
  • Language: English
  • Copyright: © Academic Press 2022
  • Published: April 15, 2022
  • Imprint: Academic Press
  • Hardcover ISBN: 9780323992831
  • eBook ISBN: 9780323992848

About the Editors

Ganji Nagaraju

Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. He received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 100 research papers in highly reputed international journals and has presented more than 50 abstracts at various national and international conferences. Dr. Nagaraju is author and editor of several published books in Elsevier and Springer Nature. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR).

Affiliations and Expertise

Assistant Professor, School of Medicine, Division of Hematology and Oncology, University of Alabama, Birmingham, USA

Sarfraz Ahmad

Doctor Sarfraz Ahmad is Director of Clinical Research at the Gynecologic Oncology Department of the Advent Health (formerly Florida Hospital) Cancer Institute (AHCI), Orlando, FL, USA. He earned his PhD degree in Biochemistry from North-Eastern Hill University, Shillong. Before joining AHCI in 2002, he spent 2-years at the Indian Institute of Technology-Delhi as a researcher, and 10-years in research/teaching at the Loyola University of Chicago and the University of Illinois at Chicago’s Division of Hematology/Oncology, College of Medicine. Currently, he is Professor of Medical Education at the University of Central Florida, College of Medicine and Professor of Clinical Sciences at the Florida State University College of Medicine, Orlando, USA. He has trained numerous fellows, residents, medical students, and graduate/undergraduate students during their scholarly research projects and theses. Dotor Ahmad’s current research focus is on the analyses of clinico-pathologic and surgical outcomes of oncology/hematology patients and to better understand the cellular/molecular mechanisms of cancer and related thrombo-embolic/hematologic disorders. His investigations are also aimed towards the evaluation of novel treatment options (chemo/cellular/immuno-therapies) for better management of hemato-oncologic patients. His past research interests focused on the anticoagulants, antithrombin, antiplatelet, and thrombolytic drug development for the management of hematologic and cardiovascular patients. In these various areas of biomedical research and international collaborations, Dr. Ahmad has published over 200 peer-reviewed scholarly research articles and book chapters, and nearly 400 scientific abstracts, which are extensively cited globally. He is a reviewer and has editorial responsibilities for several biomedical journals/books; he has received several competitive research grants and national/international awards for his research contributions/accomplishments. In addition to biomedical science endeavors, Dr. Ahmad is passionate about classical Hindi-Urdu literature & poetry and takes pride with active participation in such forums.

Affiliations and Expertise

Director of Clinical Research, Gynecologic Oncology Department of AdventHealth (formerly Florida Hospital) Cancer Institute (FHCI), Orlando, FL, USA

Ratings and Reviews

Write a review

There are currently no reviews for "Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3"